First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment

Ozaras, Reşat; Mete, Bilgül; Ceylan, Bahadir; Ozgunes, Nail; Gunduz, Alper; Karaosmanoglu, Hayat; Cagatay, Arif; Gokturk, Kadir; Erdem, Levent; Kocak, Funda; Senates, Ebubekir; Tabak, Ömer

doi:10.1097/meg.0000000000000099

First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment

Atıf İçin Kopyala

Ozaras R., Mete B., Ceylan B., Ozgunes N., Gunduz A., Karaosmanoglu H., ...Daha Fazla

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, cilt.26, sa.7, ss.774-780, 2014 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 26 Sayı: 7
Basım Tarihi: 2014
Doi Numarası: 10.1097/meg.0000000000000099
Dergi Adı: EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.774-780
İstanbul Üniversitesi Adresli: Evet

Özet

Background Hepatitis B virus (HBV) infection is a health problem worldwide. Current treatment options for chronic hepatitis B (CHB) are nucleoside or nucleotide analogues and pegylated interferons. Tenofovir and entecavir are much more commonly used as they have better efficacy, tolerability, and high genetic barriers to resistance.